• Policy
• Reevaluation deadline for listed drugs extended 5 months...
• by Kim, Jung-Ju Sep 30, 2022 05:53am

• Policy
• Research service for re-evaluation of listed drug benefits
• by Lee, Tak-Sun Sep 30, 2022 05:53am

• Policy
• Withdrawal of Hanmi's Olita permit, cancellation of benefit
• by Lee, Tak-Sun Sep 29, 2022 05:50am

• Policy
• Boryung Zepzelca, conditional approval with phase 2 data
• by Lee, Hye-Kyung Sep 29, 2022 05:49am

• Policy
• Janssen's Talquetamab, approved for Phase 3 in Korea
• by Lee, Hye-Kyung Sep 28, 2022 06:05am

• Policy
• Generic for Acelex will be released
• by Lee, Tak-Sun Sep 27, 2022 05:51am

• Policy
• Hutecs targets pitavastatin market with its lowest-price
• by Lee, Tak-Sun Sep 27, 2022 05:51am

• Policy
• MFDS in discord regarding promotion of oral COVID-19 Txs
• by Sep 26, 2022 06:08am

• Policy
• Lipiodol’s price reduced from 25th... 2-year suit dismissed
• by Kim, Jung-Ju Sep 26, 2022 06:07am

• Policy
• HCV treatment Epclusa·Vosevi start pricing negotiations
• by Lee, Tak-Sun Sep 23, 2022 05:52am